The glycolytic enzyme glucokinase plays an important role in the regulation of insuln secretion and recent studies have shown that mutations in the human glucokinas gene are a common cause of an autosomal domint form of non-inssulin-dependent (type 2) diabetes meilitus (NIIDDM) that has an onset often during childhood. The majority of the mutations that have been identified are missense mutations that result in the syntheis of a glucokinas molecule with an altered amino acid sequence. To characterize the effect of these mutations on the catalytic properties of human 3-cell glucokinase, we have expressed native and mutant forms of this protein in Eschenchia coli. AU of the missense mutations show chnges in enzyme activity including a decrease in V.. and/or increase in K. for glucose. Using a model for the threedimensional structure of human glucokinas based on the crystal structure of the related enzyme yeast hexokinae B, the mutations map primarily to two regions of the protein. One group of mutations is lcated in the active site cleft separating the two domains of the enzyme as wefl as in surface loops leading into this cleft. These mutations usually result in large reductions in enzyme activity. The second group of mutations is located far from the active site in a region that is predicted to undergo a substrate-induced conformational change that results in closure of the active site cleft. These mutations show a smail -2-fold reduction in V., and a 5-to 10-fold increase in K. for glucose. The characterization of mutations in glucokinase that are asted with a distinct and readily recognizable form of NIDDM has led to the identification of key amino acids involved in glucokinas catalysis and locaized functionaUly important regions of the glucokinas molecule.
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The phosphorylation of glucose in mammalian tissues is mediated by a family ofhexose phosphotransferases (1) (2) (3) . These include glucokinase and hexokinases I, II, and III. Glucokinase is expressed in insulin-secreting pancreatic 13 cells and hepatocytes and is characterized by a high Km and specificity for glucose and a relative lack ofproduct inhibition by glucose 6-phosphate compared to the hexokinases (4) (5) (6) . It plays an important role in regulating and integrating glucose metabolism in both tissues (3, (6) (7) (8) . In pancreatic 1 cells, glucokinase, which represents about 20%o of the total glucose phosphorylating activity, and the GLUT2 glucose transporter are believed to act in concert as the "glucose-sensing apparatus" modulating insulin release in response to changes in plasma glucose concentration (3, 9, 10) . By contrast, glucokinase provides about 80% of the total glucose phosphorylating activity in mammalian liver. In this tissue, the expression of a glucose phosphorylating activity that has a high Km for glucose and relative lack ofinhibition by glucose 6-phosphate serves to maintain a gradient for glucose entry into the hepatocyte, which is particularly important following a meal when plasma glucose levels are elevated (4, 7) .
We have recently shown that mutations in the glucokinase gene can cause an autosomal dominant form of non-insulindependent diabetes mellitus (NIDDM) with onset usually before 25 years of age (11) (12) (13) (-cell glucokinase cDNA clone, phGK-20 (15) , was used to generate the construct pEhgk-WT. An Nde I site was generated at the 5' end using PCR with an oligonucleotide that had a 1-bp mismatch (GGC TGG TGT GCA TAT GCT GGA CGA CAG). The insert in the pET 3a expression construct included the protein coding region of the cDNA as well as the 3' untranslated region.
The sequences of human 1-cell and liver glucokinase differ at their NH2 termini (13, 16 were phosphorylated, annealed, and ligated to the Nde I site of the pET 3a vector and the Pst I site of the cDNA.
Site-Directed Mutagenesis of Human (3-Cell Glucoinase. In vitro mutagenesis ofhuman 3-cell glucokinase was carried out using the Altered Sites in vitro mutagenesis system (Promega). All mutations were confirmed by DNA sequencing.
Bacterial Expression and Purification of Native Human «3Cell and Liver Glucokinases and 3-Cell Human Glucokinase Mutants. Native and mutant human glucokinases were expressed in Escherichia coli essentially as described (17, 18) . Glucokinase was purified 20-fold from extracts of E. coli in four steps, including (NH4)2SO4 precipitation (45-65%), gel filtration on a Sephadex G-100 column, chromatography on a glucosamine-Sepharose column, and FPLC Mono Q-Sepharose chromatography. The latter step was necessary to remove a small amount of low Km hexokinase activity in the cell extract that could confound kinetic studies. The purified protein was homogeneous as judged by SDS/PAGE. Native (-cell glucokinase had a specific activity of 100 units/mg, which is similar to that reported for the purified rat liver enzyme (19) . The purified recombinant protein was also subjected to NH2-terminal sequence analysis. The protein, analyzed through 12 cycles, gave the expected sequence:
Modeling of Human P-Cell Glucokinase Structure. A simple model of human p-cell glucokinase was generated using the known crystal structure of yeast hexokinase (20) (21) (22) (23) .
RESULTS
Expression of Native and Mutant Forms of Human Glucokinase in E. coUl. Mutations in the glucokinase gene associated with early-onset NIDDM have been found in 9 ofthe 12 exons ( Fig. 1 ) and include splicing, nonsense, and missense mutations, the latter of which provide an opportunity to address structure/function relationships in this important regulatory enzyme of glycolysis. To date, there has been only one study employing site-directed mutagenesis to investigate structure/ function relationships of glucokinase (18) . In that study, mutation of Asp-205 -* Ala in the rat liver enzyme resulted in a 500-fold decrease in the kcat of the reaction with no change in the Km for glucose or ATP. This finding is consistent with this carboxylate group hydrogen bonding to the phosphoryl acceptor and functioning as a general base catalyst (20) (21) (22) (23) .
The human (3-cell form of glucokinase was readily expressed in E. coli ( Fig. 2A ) using the T7 RNA polymerasebased expression system (24); easily detectable levels of glucokinase activity were found in the soluble fraction of cell extracts after 15 min of induction of expression with isopropyl P-D-thiogalactopyranoside and activity increased nearly 50-fold after 2 hr. The native and mutant forms of p-cell glucokinase were expressed at similar levels with the exception ofthe truncated form ofthe enzyme, which has a Glu-279 --amber mutation and lacks residues 279-465. We were unable to detect expression of this nonsense protein presumably because it was unstable and rapidly degraded. Like the native enzyme, all of the mutant forms were recovered in the soluble fraction and could be readily purified to homogeneity.
Effects of Missense Mutations on (-Cell Activity. The mutations showed a wide range of effects on Vn,,, and Km for glucose with no detectable effect on affinity for ATP (Table   1 ). Since the kinetic parameters of the p-cell and liver isoforms are very similar (Table 1) , we expect that these mutations will have the same effect on the activity of liver glucokinase. However, this issue needs to be addressed directly. The higher efficiency ofbacterial expression ofliver glucokinase compared to the p-cell isoform has been reported by others (25) for the corresponding rat isoforms and suggests that the first 15 NH2-terminal amino acids affect stability and/or proper folding of glucokinase in E. coli cytosol.
Structure/Function Analysis of Glucoinase Mutations. We have used the three-dimensional structure of the related protein yeast hexokinase B to develop a model of human p-cell glucokinase (13, (20) (21) (22) (23) . As shown in the alignment in (Fig. 3) , the hydrophobic character of the amino acid in this position may be very (-cell glucokinase. The single-letter abbreviations for amino acids are used. "X" indicates a nonsense mutation. The splicing mutations are as follows: K262+2Gdell5 is a 15-bp deletion that removes the T of the GT in the splice donor site of intron 4 and the following 14 bp resulting in a GG; G227-2A-*T is a mutation of the splice acceptor site in intron 6 from AG-. TG; and S418-1G-*C is a mutation of the splice acceptor site in intron 9 from AG -+ AC. The mutations that were expressed in E. coli and characterized kinetically ( important and substitution with a less hydrophobic amino acid such as Ala may alter the conformation ofthe active site. Thr-228 is a conserved amino acid in all hexokinases and glucokinases and its mutation was predicted to affect affinity for glucose and/or ATP (13) . The Thr-228 --Met mutation Glucokinase activity was determined as described (17, 18) . The values shown are the mean ± SEM of three to five separate expression experiments. The kinetic analysis was done with purified native and mutant enzyme forms. However, the same changes in kinetic properties were observed after partial purification of the enzyme by (NH4)2S04 fractionation. No active enzyme.
resulted in a large decrease in maximal velocity that could not be overcome by increasing the ATP/Mg concentration to 20 mM (data not shown). Glu-256 is predicted to hydrogen bond with glucose and its mutation to Lys resulted in a large decrease in maximal velocity but with no significant change in Km for glucose. Mutation of Glu-256 to a basic amino acid would remove this hydrogen bond and thus reduce the affinity for glucose and/or interfere with the open/closed equilibrium of the enzyme. In support of this hypothesis, the Gibbs free energy (AAG) estimated from the relative ratios of Vmax/Km of the Glu-256 -+ Lys mutation and the native enzyme is about 3.0 kcal/mol (1 kcal = 4.18 kJ), which is consistent with the energy of one hydrogen bond of 3.5-4.5 kcal/mol (26) . However, Km is not simply correlated with binding affinity, especially when a significant conformational change occurs during catalysis, so that the effect of mutation ofa binding residue such as Glu-256, or perhaps Thr-228, may be on V. rather than Km, which is what was observed.
Other mutations affect residues that are conserved between human 3-cell glucokinase and yeast hexokinase B (Val-182, Glu-279, Gly-299, and Glu-300), implying that they are functionally important. For example, Glu-300 is predicted to form a salt bridge with Arg-303, a residue that is also conserved (Fig. 3) , and mutation of Glu-300 to Lys or Asn would eliminate this interaction, which may be required for glucose binding. Consistent with this, the Lys and Asn mutants had a lower affinity for glucose (Table 1) . Several mutations such as Gly-261 -> Arg, Gly-299 -) Arg, and Leu-309 --Pro are predicted to alter the structure of the protein, and these mutations are associated with large decreases in V.. Ofthe closure (23 cleft (Gly-261, Glu-279, Gly-299, Glu-300), or very far from the active site (Leu-309) and, as described above, may affect the structure of the active site or the open-closed equilibrium of the enzyme. The mutations occurring in exon 5 are located in a surface loop preceding a-helices 3 and 4 ( Fig. 3) in the small domain, which, by analogy with the hexokinase B structure (23) , undergoes a conformational change on glucose binding, and mutations in this region may interfere with this conformational change and thereby affect glucose binding and/or catalysis.
We have previously suggested, based on the identification of a nonsense mutation that was linked with early-onset NIDDM (11) , that mutations in the glucokinase gene lead to the development of glucose intolerance by a gene-dosage mechanism. The demonstration of decreased enzymatic activity of missense mutations in glucokinase that are associated with NIDDM is consistent with this hypothesis. Decreased cellular levels of glucokinase activity may increase the glucose threshold for insulin secretion in the , cell as well as impair hepatic uptake and metabolism of glucose (3, 6, 7) . Since diabetic patients have one normal as well as one mutant glucokinase allele (11-13), they are not totally deficient but rather are predicted to have glucokinase levels that are about 50%6 of normal. However, this level of activity is apparently not sufficient to ensure normal (-cell and/or hepatocyte function since these individuals have readily detectable defects in glucose metabolism that include mild fasting hyperglycemia, impaired glucose tolerance, as well as overt NIDDM (refs. 11-13; P.F., unpublished data). Interestingly, a metabolic defect is evident even in individuals having a mutation such as Glu-300 --Gln, which has no apparent effect on V.. and only a 2-to 3-fold increase in the Km for glucose (Table 1 ). This finding suggests that the product of the mutant allele may in some instances also have an effect per se on (-cell glucose sensing and/or hepatic glucose metabolism (13) .
Glucokinase mutations may be the most common genetic cause of NIDDM identified to date, especially among young patients with NIDDM diagnosed before age 25. Studies ofthe effects of these mutations on glucokinase activity in vitro have led to the identification of key amino acid residues involved in determining glucokinase activity. The identification and functional characterization of further glucokinase mutations should lead to the identification of other key residues. These studies together with determination of the crystal structure of human (-cell glucokinase will provide new insight into the molecular mechanism responsible for the effi'cient transfer of phosphate from ATP to glucose and may lead to therapeutic approaches for treating NIDDM resulting from mutations in this important glycolytic enzyme.
